CLINICAL_TRIALS
trial_result
· 2020-07-16
Clinical Trial Update: Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors [Phase 1, Phase 2]
Summary
Dose escalation study of ADXS31-164 in HER2-expressing solid tumors has completed Phase 1/2 trials.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Advaxis, Inc. | Conditions: HER2 Expressing Solid Tumors | Phase 1, Phase 2 | Status: COMPLETED